Oxford Nanopore Partners A.D.A.M. Innovations To Advance Genomic Sequencing In Japan
KUALA LUMPUR, March 18 (Bernama) -- Oxford Nanopore Technologies and A.D.A.M. Innovations (Japanese corporate name Genesis Healthcare Co) announced an international collaboration to accelerate advanced genomic sequencing and medicine applications in Japan.
The partnership aims to develop and deploy comprehensive nanopore sequencing technology across the Japanese genetic testing market, according to Oxford Nanopore in a statement.
Oxford Nanopore Technologies, Vice President Commercial and General Manager APAC, Gretchen Weightman commented that the joint force will help bring rapid, scalable sequencing directly into clinical pathways and strengthen scientific ties between the United Kingdom (UK) and Japan.
Meanwhile, A.D.A.M. Innovations President, Michel Mommejat noted that Oxford Nanopore’s innovative platform opens new possibilities for clinical genomics in Japan and is intended to enhance diagnostic capability and advance the nation’s genomic precision medicine.
The initial phase will establish Oxford Nanopore’s information-rich, real-time sequencing technology within A.D.A.M. Innovations’ advanced genetic testing portfolio. This integration is expected to enable rapid and precise genomic testing across multiple disease areas.
The long-term goal is to introduce new clinical workflows validated under Japan-specific standards, supporting scalable sequencing of DNA fragments of any length. Sequencing that captures complete genomic information is poised to expand testing accuracy beyond existing technologies.
A memorandum of understanding was signed at the British Embassy in Tokyo, in an event supported by His Majesty’s Ambassador to Japan, Julia Longbottom.
The initiative aligns with the UK-Japan Health Memorandum of Cooperation and reflects a broader increase in bilateral life sciences collaboration, strengthening industrial cooperation and accelerating translational research for patient benefit.
-- BERNAMA